Abstract 2687: GLP-1 RA in PsA In combined Toronto + NYU cohort, GLP-1 RA significantly associated with reduced: - Weight, CRP, and pain scores - Each 1% reduction in body weight associated w/ TJC, DAPSA, EQ-5D (QoL), LDL, Systolic BP @RheumNow #ACR25 https://t.co/30lPDkALKs

• https://x.com/AkhilSoodMD/status/1983594178727571938/photo/1

Biologic choice in PsA: consider factoring in obesity ⚖️ Abstract 2691: In a longitudinal cohort study, obesity associated with ↓ odds of achieving minimal disease activity (MDA) among pts on TNFi, but not with other DMARDs @RheumNow #ACR25 https://t.co/p4KaH6HKYj

• https://x.com/AkhilSoodMD/status/1983591933143330833/photo/1

Abstract 2690: Food as a Medicine Mediterranean vs low-calorie DASH vs control diet in PsA (multicenter RCT): 🔹 All 3 groups showed significant weight loss & DAPSA by wk 24 🔹 Weight loss not diet type may be the driver of clinical improvement @RheumNow #ACR25 https://t.co/rBS3HR1HXl

• https://x.com/AkhilSoodMD/status/1983589421267009836/photo/1

In a 5-year EHR-based cohort, PsO patients initiating IL-17i had significantly lower incidence of PsA/IA vs IL-23i, IL-12/23i, or TNFi. IL-17i reduced time with PsA/IA by 45% vs IL-23i, 61% vs IL-12/23i, and 74% vs TNFi. Further research need investigate if IL-17i may delay https://t.co/0PTbXZpLbu

• https://x.com/synovialjoints/status/1983587134218101066/photo/1

In PsA patients, GLP-1 RA therapy led to significant weight loss and improvements in CRP, pain, lipids, and blood pressure. PsA outcomes improved proportionally with weight loss. Regression analyses revealed that each 1% reduction in body weight was associated with significant https://t.co/Pph1PjfOve

• https://x.com/synovialjoints/status/1983579582700654723/photo/1

Deucravacitinib (TYK2) in PsA from POETYK trials Improved ACR20 at wk16 (NNT ~5), less benefit for ACR70 (NNT ~20) Steady improvements during open label extension (all pts received drug) Would expect approval for PsA soon... where will this fit in your approach? @RheumNow https://t.co/325h2hf0AE

• https://x.com/EBRheum/status/1983566474951393426/photo/1
• https://x.com/EBRheum/status/1983566474951393426/photo/1

#ACR25 Clinical Preview by Prof Coates for use now: GLP-1 agonist & Diet Abstr#813 GIP/GLP-1 improved MSK pain Abstr#849 GLP-1 reduced risk of #MACE in PsA Abstr#2690 RCT = the degree of weight loss regardless specific dietary strategy determined benefit in PsA @RheumNow https://t.co/4jB0fFHosC

• https://x.com/Yuz6Yusof/status/1983564323973640562/photo/1
• https://x.com/Yuz6Yusof/status/1983564323973640562/photo/1
• https://x.com/Yuz6Yusof/status/1983564323973640562/photo/1

Does diet matter in PsA? Randomized study comparing advice, DASH low calorie, Mediterranean diet Seems that weight loss corresponds better with benefit than diet. BMI reduction remains focus in PsA Laura Coates #ACR25 meeting review @RheumNow https://t.co/CqR25sJdDc

• https://x.com/drdavidliew/status/1983559618363281849/photo/1

Impact on handedness in PsA disease activity and structural damage: a question that often comes in my practice Comments on Abstract #1415 presented at #ACR25 https://t.co/GilOFvXajJ @RheumNow

• The Upper Hand in PsA? Not the Dominant One | RheumNow

#ACR25 Clinical Review by Prof Coates @DrLauraCoates to be applied tomorrow! Early Diagnosis/Tx Abstr#2689 EHR study = IL-17i could prevent #PsA vs IL-23/TNFi Abstr#576 Oligo → Polyarthritis progression in women, no DMARD, enthesitis, dactylitis, nail psoriasis @RheumNow https://t.co/e1hCERpCNW

• https://x.com/Yuz6Yusof/status/1983553686463721895/photo/1
• https://x.com/Yuz6Yusof/status/1983553686463721895/photo/1

Clinical Year in Preview SpA: no difference in efficacy rotating vs switching bDMARD MoA for next steps @RheumNow #ACR25 #LB09 https://t.co/shCLgk7Yqz

• https://x.com/JihaRheum/status/1983553108535136270/photo/1

Do biologics prevent PsA? Retro cohort analysis EHR through natural language processing 5 years trends PsO treated w/ IL-17i had lower incidence of PsA/IA than pts treated w/ IL-23i, IL-12/23i, or TNFi therapies Adjustment on several confounding Prospective data heavily https://t.co/W9MFaWNbWC

• https://x.com/AurelieRheumo/status/1983552472221163564/photo/1

ACR25 coming to a close with Clinical Year in Preview For PsA, can biologics prevent damage? If so, which one? Difficult to answer often b/c confounding by indication. NLP-informed propensity matching beyond demographics for clinical factors like BSA @RheumNow #ACR25 A#2689 https://t.co/jjpb0kTo34

• https://x.com/JihaRheum/status/1983551740202095038/photo/1

#YearInPreview at #ACR25 @DrLauraCoates introduces the session with a teaser for work that will be presented later today. Are we entering an era in which we will be able to prevent #PsA? Find out more at 12:00 today, Abs #2689 @RheumNow https://t.co/GDTBGNTCCd

• https://x.com/DrMiniDey/status/1983551437800923182/photo/1